Morse Asset Management Inc Has $2.61 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Morse Asset Management Inc grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 122.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,119 shares of the biopharmaceutical company's stock after buying an additional 2,264 shares during the period. Morse Asset Management Inc's holdings in Regeneron Pharmaceuticals were worth $2,612,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Marietta Wealth Management LLC grew its holdings in Regeneron Pharmaceuticals by 30.2% during the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after buying an additional 2,501 shares in the last quarter. Pamalican Asset Management Ltd purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $4,915,000. Rhenman & Partners Asset Management AB increased its stake in Regeneron Pharmaceuticals by 11.4% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock worth $30,956,000 after acquiring an additional 4,457 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after acquiring an additional 814,713 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Regeneron Pharmaceuticals by 3.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after acquiring an additional 955 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Argus downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Wall Street Zen lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. Robert W. Baird decreased their price target on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research note on Friday, April 25th. Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price target for the company. Finally, Citigroup decreased their target price on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a research note on Monday, June 2nd. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $823.54.

Regeneron Pharmaceuticals Stock Up 0.6%

NASDAQ REGN traded up $3.01 on Monday, hitting $545.53. The stock had a trading volume of 708,622 shares, compared to its average volume of 928,922. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $1,211.20. The business's fifty day moving average price is $544.44 and its 200 day moving average price is $613.61. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The stock has a market cap of $58.90 billion, a price-to-earnings ratio of 13.89, a price-to-earnings-growth ratio of 2.04 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm's revenue was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $9.55 EPS. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were paid a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.65%. Regeneron Pharmaceuticals's dividend payout ratio is presently 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.